Vivo Capital’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
Vivo Capital's AVTX Position: Q3 2026 in Review
Vivo Capital held its Avalo Therapeutics (AVTX) position steady in Q3 2026 at 275,000 shares worth $4.22M. The position accounts for 0.46% of the portfolio, ranked #42.
Vivo Capital first reported a position in AVTX in Q2 2026 and has held it in 2 quarters since. The position peaked at $5.08M in Q2 2026. 148 funds tracked by Wall St. Rank hold AVTX as of Q3 2026.
- Vivo Capital held 275,000 shares of Avalo Therapeutics worth $4.22M as of Q3 2026.
- Vivo Capital left its Avalo Therapeutics share count unchanged in Q3 2026.
- Avalo Therapeutics made up 0.46% of Vivo Capital's portfolio in Q3 2026, its #42 holding.
- Vivo Capital first reported a position in Avalo Therapeutics in Q2 2026 and has held it in 2 quarters since.
- Vivo Capital's Avalo Therapeutics position peaked at $5.08M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2026.
Based on Vivo Capital's 13F filing for Q3 2026, filed 13 Nov 2026.